Target Solvent
Bacteriostatic Water (0.9% Benzyl Alcohol)
Store refrigerated
Validated Laboratory Standard
Revision 1 · Lyophilized Solid Powder
Endogenous Human Incretin Reference Standard. Formulated for in-vitro research and laboratory analytical validation.
Endogenous Human Incretin Reference Standard. Formulated for in-vitro research and laboratory analytical validation.
GLP-1 Native (7-36 Amide) is the biologically active endogenous human peptide hormone synthesized and secreted by intestinal L-cells in response to nutrient intake. Truncated from proglucagon, GLP-1(7-36) amide binds with picomolar affinity to the human GLP-1 receptor, stimulating glucose-dependent insulin secretion. Due to rapid degradation by dipeptidyl peptidase-4 (DPP-4; half-life 1.5–2 minutes), it serves as the essential positive control standard for incretin binding and enzymatic cleavage assays.
Target Solvent
Bacteriostatic Water (0.9% Benzyl Alcohol)
Store refrigerated
Diluent Ratio
2 mL per 5 mg (2.5 mg/mL)
Slow laminar stream against vial wall; keep cold on wet ice.
Lyophilized Storage
Store at -20°C desiccated.
Desiccated and protected from thermal spikes
Liquid Stability
Use immediately or aliquot at -80°C.
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~2 to 3 Minutes (Rapid DPP-4 cleavage in plasma)
Typical protocol duration: Acute In Vitro / In Vivo Assays; Washout: 24 Hours
| Standard Compound Mass | 5 mg active per vial |
| Recommended Diluent | Bacteriostatic Water (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 2.5 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 25.0 mcg (0.01 mL)) |
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (5mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Assay Day 1) | 25 mcg | 1.0 Units(0.01 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Assay Day 2) | 50 mcg | 2.0 Units(0.02 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Assay Day 3) | 100 mcg | 4.0 Units(0.04 mL) | 1x Daily |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 25 mcg | 0.010 mL | 1 Units 1 unit |
| 50 mcg | 0.020 mL | 2 Units 2 units |
| 100 mcg | 0.040 mL | 4 Units 4 units |
| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 25 mcg | 0.01 mL (10 µL) | 1 Units | 1 unit |
| 50 mcg | 0.02 mL (20 µL) | 2 Units | 2 units |
| 100 mcg | 0.04 mL (40 µL) | 4 Units | 4 units |
| Vial Net Mass | BAC Water | Concentration | 2.5 mg Dose | 5.0 mg Dose | 7.5 mg Dose | 10.0 mg Dose | Recommended Phase |
|---|---|---|---|---|---|---|---|
| 10 mg Vial | 2.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | — (Requires 20mg) | — (Requires 20mg) | Weeks 1–8: Initiation & Early Titration |
| 15 mg Vial | 3.0 mL | 5.0 mg/mL | 50 units (0.50 mL) | 100 units (1.00 mL) | 150 units (1.50 mL) | — | Extended low-dose or intermediate titration |
| 20 mg Vial | 2.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 9+: High-Dose Escalation |
| 30 mg Vial | 3.0 mL | 10.0 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 75 units (0.75 mL) | 100 units (1.00 mL) | Weeks 13+: High-Dose Maintenance |
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 1 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 1 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 1 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 1 units |
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for GLP-1 Native.
Do NOT reconstitute all 1 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.9mg rem) | 0.1 mg / 1.2 mg |
| Week 2 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.8mg rem) | 0.2 mg / 1.2 mg |
| Week 3 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.7mg rem) | 0.3 mg / 1.2 mg |
| Week 4 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.6mg rem) | 0.4 mg / 1.2 mg |
| Week 5 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.5mg rem) | 0.5 mg / 1.2 mg |
| Week 6 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.4mg rem) | 0.6 mg / 1.2 mg |
| Week 7 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.3mg rem) | 0.7 mg / 1.2 mg |
| Week 8 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.2mg rem) | 0.8 mg / 1.2 mg |
| Week 9 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4.1mg rem) | 0.9 mg / 1.2 mg |
| Week 10 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(4mg rem) | 1.0 mg / 1.2 mg |
| Week 11 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(3.9mg rem) | 1.1 mg / 1.2 mg |
| Week 12 | Maximal Stimulus (Assay Day 3) | 100 mcg | 4 Units(0.04 mL) | Vial #1(3.8mg rem) | 1.2 mg / 1.2 mg |
Study duration: Acute In Vitro / In Vivo Assays · Washout: 24 Hours
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Assay Day 1Starting Baseline | 25 mcg | Acute | Baseline Control: Receptor binding kinetics (1 unit on U-100 syringe) |
| Assay Day 2 | 50 mcg | Acute | Functional Response: Glucose clamp insulin release (2 units on U-100 syringe) |
| Assay Day 3 | 100 mcg | Acute | Maximal Stimulus: Satiety signaling control (4 units on U-100 syringe) |
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for GLP-1 Native
Operating Window: +2°C to +8°C (36°F to 46°F)
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
Slow laminar stream against vial wall; keep cold on wet ice.
GLP-1 Native (7-36 Amide) displays an estimated half-life of ~2 to 3 Minutes (Rapid DPP-4 cleavage in plasma). Typical study protocols run for Acute In Vitro / In Vivo Assays followed by a washout period of 24 Hours.
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Standard Lyophilized Monograph
Endogenous Human Incretin Reference Standard. Formulated for in-vitro research and laboratory analytical validation.
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 5 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 2.50 mg/mL | 1 Unit = 25.0 mcg (0.01 mL) |
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 25 mcg | 1.0 Units (0.010 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 37.5 mcg | 1.5 Units (0.015 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 25 mcg | 1.0 Units (0.010 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA